Genomic and structural insights into the in vivo development of cefiderocol resistance in Klebsiella pneumoniae.
9 affiliations
- 1Biomedical and Biotechnological Sciences Program, University of La Rioja, 26006, Logroño, Spain. [email protected].
- 2Difficult-to-Diagnose and Treat Infections Research Group, Institute for Health Research Aragon, Miguel Servet University Hospital, 50009, Saragossa, Spain. [email protected].
- 3Clinical Microbiology Laboratory, Miguel Servet University Hospital, 50009, Saragossa, Spain. [email protected].
- 4Difficult-to-Diagnose and Treat Infections Research Group, Institute for Health Research Aragon, Miguel Servet University Hospital, 50009, Saragossa, Spain.
- 5Clinical Microbiology Laboratory, Miguel Servet University Hospital, 50009, Saragossa, Spain.
- 6Department of Microbiology, Faculty of Medicine, University of Zaragoza, 50009, Saragossa, Spain.
- 7Infectious Diseases Department, Miguel Servet University Hospital, 50009, Saragossa, Spain.
- 8Department of Infection Control and Hospital Epidemiology, Faculty of Health Sciences, One Health Institute, University of Debrecen, 4032, Debrecen, Hungary.
- 9Area of Biochemistry and Molecular Biology, One Health-UR Research Group, University of La Rioja, 26006, Logroño, Spain.
Abstract
Cefiderocol is a newly developed siderophore-conjugated cephalosporin specifically designed to overcome multidrug-resistant (MDR) Gram-negative bacilli. Nevertheless, reduced susceptibility and resistance to cefiderocol has increasingly been reported, especially derived from alterations in iron transport systems and plasmid-mediated determinants and the expression of structural variants of β-lactamases. Moreover, cefiderocol resistance derived from target alteration remains insufficiently defined. This work aimed to characterize the genomic and structural basis of cefiderocol resistance emerging in vivo during therapy in Klebsiella pneumoniae. Comparative genomics revealed conserved plasmid architecture and no acquisition of novel β-lactamases or iron-uptake determinants. Eighty-two chromosomal variants were identified, among which a missense substitution in ftsI (FtsI G306V), located adjacent to the catalytic serine (S307) of PBP3, emerged as a plausible resistance determinant. Structural modelling suggests that the G306V substitution introduces a significant side-chain volumetric increase, resulting in locally increased steric hindrance within the active-site, possibly impairing cefiderocol interaction with its target. The absence of canonical iron-transport alterations further distinguishes this case from the predominant mechanism described in global molecular epidemiology studies. Large-scale genomic screening revealed a very low prevalence of substitutions affecting ftsI, including in resistance isolates, although possible clonal expansion cannot be ruled out. Our findings align with the broader epidemiological landscape in which cefiderocol resistance is heterogeneous and flexible. Therefore, incorporating analysis of ftsI variants within or proximal to the active-site into genomic surveillance frameworks could improve resistance detection to this last-resort antibiotic. KEY POINTS: • Resistance occurred without alterations in iron-uptake systems or siderophore pathways. • Mutations in FtsI (G306V) and AcrR (E91K) were identified as key candidates. • FtsI G306V is rare across cefiderocol resistant and global K. pneumoniae genomes.
Related
- Lactobacillus derived small RNAs protect against Klebsiella pneumoniae infection
- Ligand binding remodels the oligomeric state and active site of Klebsiella pneumoniae azoreductase
- Comparative genomics of hypervirulent Klebsiella pneumoniae isolates from Brazil
- Microbiome changes associated with FMT-mediated clearance of antibiotic-resistant Klebsiella pneumoniae in a murine carriage model
- In Silico Design and Immunogenicity Studies of Two Multi-Epitope Vaccines against Klebsiella pneumoniae.
BibTeX
@article{tristanchobaro2026genomic,
title = {{Genomic and structural insights into the in vivo development of cefiderocol resistance in Klebsiella pneumoniae.}},
author = {Alexander Tristancho-Baró and Ana Isabel López-Calleja and Ana Milagro-Beamonte and Blanca Fortuño and Juan Manuel García-Lechuz and Rosa Martínez and Ruth Caballero and Miriam Latorre-Millán and Laura Clusa and Lilla Buzgó and Carmen Torres and Antonio Rezusta},
journal = {Applied microbiology and biotechnology},
year = {2026},
month = jul,
doi = {10.1007/s00253-026-13967-y},
url = {https://europepmc.org/article/MED/42901976},
note = {CC BY},
}
RIS
TY - JOUR
TI - Genomic and structural insights into the in vivo development of cefiderocol resistance in Klebsiella pneumoniae.
AU - Alexander Tristancho-Baró
AU - Ana Isabel López-Calleja
AU - Ana Milagro-Beamonte
AU - Blanca Fortuño
AU - Juan Manuel García-Lechuz
AU - Rosa Martínez
AU - Ruth Caballero
AU - Miriam Latorre-Millán
AU - Laura Clusa
AU - Lilla Buzgó
AU - Carmen Torres
AU - Antonio Rezusta
PY - 2026
DA - 2026/07/01
JO - Applied microbiology and biotechnology
DO - 10.1007/s00253-026-13967-y
UR - https://europepmc.org/article/MED/42901976
AB - Cefiderocol is a newly developed siderophore-conjugated cephalosporin specifically designed to overcome multidrug-resistant (MDR) Gram-negative bacilli. Nevertheless, reduced susceptibility and resistance to cefiderocol has increasingly been reported, especially derived from alterations in iron transport systems and plasmid-mediated determinants and the expression of structural variants of β-lactamases. Moreover, cefiderocol resistance derived from target alteration remains insufficiently defined. This work aimed to characterize the genomic and structural basis of cefiderocol resistance emerging in vivo during therapy in Klebsiella pneumoniae. Comparative genomics revealed conserved plasmid architecture and no acquisition of novel β-lactamases or iron-uptake determinants. Eighty-two chromosomal variants were identified, among which a missense substitution in ftsI (FtsI G306V), located adjacent to the catalytic serine (S307) of PBP3, emerged as a plausible resistance determinant. Structural modelling suggests that the G306V substitution introduces a significant side-chain volumetric increase, resulting in locally increased steric hindrance within the active-site, possibly impairing cefiderocol interaction with its target. The absence of canonical iron-transport alterations further distinguishes this case from the predominant mechanism described in global molecular epidemiology studies. Large-scale genomic screening revealed a very low prevalence of substitutions affecting ftsI, including in resistance isolates, although possible clonal expansion cannot be ruled out. Our findings align with the broader epidemiological landscape in which cefiderocol resistance is heterogeneous and flexible. Therefore, incorporating analysis of ftsI variants within or proximal to the active-site into genomic surveillance frameworks could improve resistance detection to this last-resort antibiotic. KEY POINTS: • Resistance occurred without alterations in iron-uptake systems or siderophore pathways. • Mutations in FtsI (G306V) and AcrR (E91K) were identified as key candidates. • FtsI G306V is rare across cefiderocol resistant and global K. pneumoniae genomes.
SN - 0175-7598
SN - 1432-0614
ER -